Lilly Pharmaceuticals - Search News

Eli Lilly posts mixed quarter

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Business Insider · 1d

LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in

NBC Washington · 1d

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

CNBC on MSN · 1d

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,

1hon MSN

Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...

2d

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

1d

Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Hosted on MSN1d

Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds Expectations

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

Lilly expands GLP-1 research to hypertension, neuro conditions

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

1don MSN

Eli Lilly reports mixed earnings, increases 2025 guidance

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

FierceBiotech1d

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

1don MSN

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results